Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hyperprogression Upon Cemiplimab Alone or With Chemotherapy in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial - HYPERBOLIC Trial

NCT07274384 is registered in ClinicalTrials.gov with Università Vita-Salute San Raffaele as lead sponsor.

NCT NCT07274384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07274384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hyperprogression Upon Cemiplimab Alone or With Chemotherapy in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial - HYPERBOLIC Trial
Lead sponsor
Università Vita-Salute San Raffaele
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 1, 2026
Completion date
June 1, 2030
Enrollment
74 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hyperprogression, nsclc (non-small cell lung cancer)